Success of Ureteral Stents for Intrinsic Ureteral Obstruction by Wenzler, David L. et al.
295
JOURNAL OF ENDOUROLOGY
Volume 22, Number 2, February 2008
© Mary Ann Liebert, Inc.
DOI: 10.1089/end.2007.0201
Success of Ureteral Stents for Intrinsic Ureteral Obstruction
DAVID L. WENZLER, B.S., SIMON P. KIM, M.D., M.P.H., HENRY M. ROSEVEAR, B.A., 
GARY J. FAERBER, M.D., WILLIAM W. ROBERTS, M.D., and J. STUART WOLF, JR., M.D.
ABSTRACT
Purpose: Previous reports suggest a high success rate for retrograde ureteral stenting for intrinsic ureteral
obstruction, but few preoperative predictors of success have been offered. We reviewed our experience to look
for factors that suggest failure of stents for intrinsic ureteral obstruction.
Materials and Methods: We retrospectively reviewed the outcome of retrograde ureteral stent placement for
intrinsic ureteral obstruction without concurrent or intended definitive management of the obstruction.
Results: Thirty-eight patients treated for intrinsic ureteral obstruction, representing 41 ureteral units (UUs),
were monitored for an average of 25.5 months. The overall success rate was 88%. Of the successes, 13 UUs
had definitive therapy to permanently remove the cause of obstruction, obstruction resolved in 12 UUs after
stent placement, and 11 UUs were managed with indwelling stents. Therapy failed in five UUs, with a median
time to failure of 1.9 months. Of the UUs in which failure occurred, three failures were caused by misdiag-
nosis; in the remaining two, the stent did not correct the obstruction. On univariate analysis, male sex (P 
0.006), increased creatinine level as a presenting symptom (P  0.002), and more severe preoperative hy-
dronephrosis (P  0.042) were predictive of failure. Adverse events were low, with complications from stent-
ing occurring on only four of 41 UUs.
Conclusion: If initial stent placement was possible, intrinsic ureteral obstruction was managed successfully
in 88% of patients. Given high success and minimal complications, retrograde placement of ureteral stents
can be performed to treat patients with intrinsic ureteral obstruction. Treatment failure is more likely to oc-
cur in men and patients with severe hydronephrosis or an elevated creatinine level.
INTRODUCTION
INTRINSIC URETERAL OBSTRUCTION can cause signif-icant morbidity and mortality. Retrograde placement of
ureteral stents has been used as primary therapy for many causes
of intrinsic ureteral obstruction, with success rates varying be-
tween 70% and 100%.1–5 The alternative to retrograde stent
placement is percutaneous nephrostomy tube placement. While
reported health-related quality of life for patients with percuta-
neous nephrostomy tubes and patients with ureteral stents is
similar, there is often patient preference for ureteral stents when
given the option.6
Several investigators have reported significant complications
with ureteral stent placement, especially infectious complica-
tions.7–10 Ureteral stents also can significantly impact quality
of life.11,12 Given the morbidity and impact associated with
ureteral stents, clinicians would benefit from knowing the like-
lihood of success of stent placement.
Few studies have examined predictors of stent success at re-
lieving intrinsic ureteral obstruction.4 Experience suggests that
the majority of patients with intrinsic ureteral obstruction that
is managed with a ureteral stent for a short period (i.e., a few
weeks) do well. There is less experience and less published data
on longer term stenting for intrinsic ureteral obstruction.
Given this minimal data, we reviewed our institution’s ex-
perience with the management of intrinsic ureteral obstruction
using retrograde stent placement. To focus our study on pa-
tients with a longer duration of stenting, we limited our re-
view to patients who underwent retrograde stent placement
for the management of intrinsic ureteral obstruction without
definitive treatment performed at the time of stent placement
or planned for shortly thereafter. We attempted to identify de-
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mographic, clinical, or radiographic markers for successful
management.
MATERIALS AND METHODS
We retrospectively reviewed records of all patients treated
at the University of Michigan Health System for intrinsic
ureteral obstruction with initial retrograde ureteral stent place-
ment (4.8F, 6F, 7F, or 16F Percuflex® stents [Boston Scien-
tific, Natick, MA]) from November 1995 to October 2003. The
diameter of the stent was selected by the attending physician,
without a systematic protocol. Patients in whom initial stenting
was unsuccessful were not considered for the study, nor did we
include patients with initial stenting at the time of definitive
therapy for the obstruction (calculus, ureteral tumors, etc.) or
in whom definitive therapy was planned at a short interval.
Meeting these inclusion criteria were 54 consecutive patients,
for a total of 59 ureteral units (UUs), treated by one of fifteen
urologists. Eight patients, representing 10 UUs, were excluded
because of lack of follow-up, and 8 patients, representing 8
UUs, were excluded because the stent was in a transplanted
ureter. After the exclusions, there were 38 patients and 41 UUs
for analysis.
Preprocedural and postprocedural demographic, clinical,
and radiographic data were collected via examination of elec-
tronic medical records. Yossepowitch and associates3 defined
intrinsic obstruction as obstruction caused by stone disease,
ureteropelvic junction obstruction, and ureteral stricture. In
addition to these diagnoses, we also included intrinsic ob-
struction caused by malignancies of the upper tract and other
(not at the ureteropelvic junction) congenital defects of the
urinary tract (eg, mega-ureter). Ureteropelvic junction ob-
struction was classified as either a congenital defect or a stric-
ture, depending on whether the patient had or had not received
previous treatment, respectively. An additional diagnostic cat-
egory of “other” was created for patients who had ureteral ob-
struction within the ureteral lumen that did not fit one of the
other diagnostic categories.
Obstruction level was defined as proximal, mid, or distal
ureter based on the location of the obstruction above, at, or be-
low the sacroiliac joints. Hydronephrosis was graded using the
most recent ultrasonography, CT, or magnetic resonance imag-
ing before stent placement. The grade of hydronephrosis was
retrospectively assigned according to the guidelines of the So-
ciety for Fetal Urology.3
Treatment failure was defined as any UU that required an
additional procedure to manage ureteral obstruction or any UU
that continued to cause symptoms for the patient after stent
placement. Patients who elected to undergo definitive therapy
after successful treatment with a stent were not designated as
having a treatment failure. The date on which obstruction re-
solved with stenting therapy in those UUs was the date the stent
was removed.
Statistical analysis was conducted using an analysis of vari-
ance test for continuous data approximating the normal distri-
bution. Chi-square tests were used to compare categorical data.
P values  0.05 were considered statistically significant. All
analyses were conducted on commercially available software.
RESULTS
The study population consisted of 38 patients (14 men and
24 women) who represented 41 UUs (16 male and 25 female)
managed for intrinsic ureteral obstruction with retrograde
ureteral stent placement. The mean age of all patients was 52
years (range 12 to 84 years). Thirty-five patients had unilateral
obstruction, and three patients had bilateral obstruction. Each
UU was analyzed separately. Success was achieved in 36 of 41
(87.8%) patients.
The mean and median durations of follow-up in the 36 UUs
with successful management were 26.5 and 9.9 months, re-
spectively. The mean and median indwelling times of each stent
among those with successful stenting were 5.4 and 4.0 months,
respectively. Among the 36 UUs, 13 (36%) received definitive
therapy in the form of corrective surgery at some point after
stent placement. Of the 13 UUs that were managed definitively,
eight UUs had ureteropelvic junction obstruction. Of these, five
UUs were managed with endopyelotomy, one with pyeloplasty,
and two with nephrectomy.
Two cases of ureteral stricture were managed with balloon
dilation. Renal cyst resection, percutaneous treatment, and
lithotripsy with stone basketing were used for ureteral obstruc-
tion caused by a renal sinus cyst, infundibular stenosis, and
ureterolithiasis, respectively. Of the UUs that received defini-
tive management, the mean and median times between place-
ment of the stent and therapy were 3.5 and 1.2 months, re-
spectively. Both the mean and median number of stents used
in each treated UU was 2.0.
In the remaining 23 cases of successful management with
ureteral stents, there was either resolution of the problem (n 
12) or stent exchanges were continuing (n  11) at the time of
last follow-up or at the time of the patient’s death. Of the 12
with resolution, four were associated with stone passage (mean
stenting duration of 1.5 months) and in eight the inflammatory
process that caused obstruction resolved (prolonged ureteral in-
flammation after surgery in four, transient obstruction from in-
fection in four).
Of the obstructed ureters in which resolution occurred, eight
UUs had resolution after placement of the first stent and four
required additional stents. The mean and median number of
stents needed for resolution was 2.3 and 1, respectively. The
mean and median time from stenting to resolution was 11.3 and
3.4 months, respectively.
Of the 11 UUs managed with chronic indwelling stents and
periodic stent exchanges, three had ureteropelvic junction ob-
struction (all secondary), five were caused by strictures, one
was caused by an endoscopically unresectable malignancy of
the renal pelvis, one was caused by a large calculus for which
definitive treatment was declined, and one was caused by an
obstructing renal mass in a patient with metastatic renal cell
carcinoma. In the patients treated longer term with stents, the
mean and median number of stents placed was 9.0 and 6.5, re-
spectively. The mean and median times between stent ex-
changes for this group were 5.6 and 4.2 months, respectively.
The mean and median times of stenting in this group were 43.6
and 39.4 months, respectively.
Of the five failures, the mean and median times to failure
were 2.0 and 1.9 months, respectively. Both UUs failed in a
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42-year-old man with what appeared to bilateral ureteral stric-
tures; a subsequent diagnosis was e ureteral obstruction sec-
ondary to neurogenic bladder. Bilateral percutaneous nephros-
tomy tubes were placed (1.9 months after stenting) to drain the
kidneys while the neurogenic bladder was addressed.
A 13-year old boy with distal ureteral obstruction secondary
to posterior urethral valves (resected in the past) who presented
with an increasing serum creatinine level had stent placement
in an effort to preserve renal function. A subsequent renal scan
showed poor function of the kidney, and the stent was removed
4 months later.
A 69-year-old man with urothelial cancer had bilateral
ureteral obstruction, at the distal ureter on one side and the prox-
imal ureter on the other, superimposed on a degree of bilateral
distal ureteral obstruction from previous radiotherapy. Bilateral
percutaneous nephrostomy tubes were placed 1 month later for
adequate renal drainage, and the patient died of metastatic can-
cer 5 months after stent placement.
Thus, of the five failures, three were caused by misdiagno-
sis (neurogenic bladder in two UU, poor renal function in one
UU), and only two were caused by absolute failure of the stents.
Of the patients, five (with 6 UUs) died with ureteral stents
in place. Mean and median survival times after stent placement
were 19.9 and 5.8 months, respectively (range 2.1 to 93.0
months). One patient (two UUs) was the above-noted patient
with urothelial cancer who received percutaneous nephrostomy
tubes; the stents had not been removed. The patient with ob-
struction from a renal mass died of metastatic renal cancer. An-
other patient had planned to undergo definitive therapy, but was
ill on the planned surgical date and died shortly thereafter. The
two remaining patients had indwelling stents with routine
changes for several years before their deaths.
Multiple stents were placed in 24 (65%) of the successfully
managed UU, for a total of 129 stents. The mean and median
total number of stents were 5.3 and 3.0, respectively (range 2
to 23). The mean and median intervals between stent exchanges
were 5.8 and 3.1 months, respectively.
Table 1 summarizes variables compared with outcome. Pre-
senting symptom (P  0.002), degree of preoperative hy-
dronephrosis (P  0.042), and patient sex (P  0.006) were sta-
tistically significantly associated with stent success. Stents for
pain and other symptoms had high success rates (92% and
100%, respectively), compared with stents for increased crea-
tinine level (40%).
UUs associated with no or mild hydronephrosis had 100%
successful management with stenting. Moderate and severe hy-
dronephrosis had less success; stenting relieved obstruction
82% and 63% of the time, respectively. Women also appeared
to be treated more effectively than men. Of the women, 100%
had successful treatment, compared with only 69% of the men.
Patient age at the time of stent placement (data not shown) was
not a significant predictor of success (P  0.58).
Complications were minimal. Thirty-seven UUs (90 %) of
the 41 UUs managed did not have complications from stenting
procedures. Two patients (3 UUs) experienced pyelonephritis
after stent exchange. One patient (1 UU) had an episode of post-
operative hypotension and myocardial infarction.
DISCUSSION
Several investigators have noted high success rates with ret-
rograde ureteral stenting to manage intrinsic ureteral compres-
sion. Barbalias and colleagues4 used retrograde stent placement
as primary therapy in patients with recurrent ureteropelvic junc-
tion obstruction, and three (75%) of four patients had no fur-
ther therapy after a mean of 16 months. Reinberg and associ-
ates1 treated five patients who had ureteral strictures from
various causes that were refractory to other treatment. They
used Wallstent placement, and after a follow-up period of 6 to
24 months, all stents remained patent.
Leventhal and coworkers2 determined that stent placement
can aid in the passage of stones as large as 10 mm from the
distal ureter in 83% of patients and prevent the need for surgi-
cal intervention to remove the stones. Yossepowitch and asso-
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TABLE 1. VARIABLES AND OUTCOME
Success All % Success P valuea
Sex
Men 11 16 69b,c 0.006
Women 25 25 100b,c
Race
White 32 37 86b,c 0.99
Other 4 4 100b,c
Location
Proximal 24 26 92b,c 0.37
Middle 2 3 67b,c
Distal 10 12 83b,c
Side
Right 18 20 90b,c 0.68
Left 18 21 86b,c
Symptoms
Pain 24 26 92b,c 0.002
Increased 2 5 40b,c
creatinine
Other 10 10 100cb,
Stent diameter
4.8F 1 1 100b,c 0.871
6F 26 31 84b,c
7F 5 5 100b,c
8F 3 3 100b,c
16Fd 1 1 100b,c
Causes
Congenital 5 6 83b,c 0.26
Stricture 17 19 89b,c
Calculus 6 6 100b,c
Malignancy 3 5 60b,c
Other 5 5 100b,c
Hydronephroses
None 14 14 100b,c 0.042
Mild 8 8 100b,c
Moderate 9 11 82b,c
Severe 5 8 63b,c
aFor comparison between successful and failed patients.
b,cIndicates pair with Bonferroni-corrected P  0.95 for be-
tween-group comparison.
dThe 16F stent was an externalized single pigtail stent in a
patient with an ileal loop urinary diversion.
ciates3 noted 100% stent patency after 3 months in patients with
intrinsic ureteral obstruction caused by stones, ureteropelvic
junction obstruction, and ureteral stricture.
Our study examined all causes of intrinsic ureteral obstruc-
tion and found an overall success rate of 88% after a mean fol-
low-up interval of 25.5 months. Failure of the stent to provide
adequate drainage was not related to the cause of obstruction.
Few investigators have addressed such a large cohort of pa-
tients with intrinsic causes of ureteral obstruction as we have
presented. None have examined exclusively patients with in-
trinsic ureteral obstruction and attempted to predict stent suc-
cess or failure based on preoperative data.
In 2001, Yossepowitch and associates3 examined 61 cases
of intrinsic and 39 cases of extrinsic ureteral obstruction, not-
ing that, in addition to having significantly greater success rates
when managing intrinsic disease, a greater degree of hy-
dronephrosis was the only significant predictor of stent failure
in the intrinsic group.
Our data also suggest that more severe hydronephrosis is a
significant predictor of failure. Increasing severity of hy-
dronephrosis may indicate a greater degree of ureteral obstruc-
tion. This affords little opportunity for urine to drain around the
stent, which may explain the poorer success rates.
In addition, our study also shows that clinical presentation
and sex were significant predictors of stent failure. Patients pre-
senting with an increased creatinine level caused by ureteral ob-
struction had significantly poorer outcomes than patients pre-
senting with flank pain or other symptoms. An increasing
creatinine level does not necessarily imply postrenal obstruc-
tion within the ureter. Both intrinsic kidney disease and ob-
struction distal to the ureter can explain why stenting would im-
prove neither hydronephrosis nor serum creatinine values. Men
also failed stent therapy significantly more often than women.
A significant proportion of our patients sought definitive
treatment. Although these patients were not permanently treated
with stenting, all had obstruction corrected were safely before
definitive treatment. Several other patients were treated suc-
cessfully with stenting and either had resolution of their disease
or continued with stent exchanges until death. These procedures
were also performed safely in the majority of patients. In con-
trast to other investigators who have shown complications in as
many as 36% of their patients, complications occurred in only
four (10%) of 41 stented UUs in our study.8
Of the five failures, 3 were because of misdiagnosis, and
only two were caused by failure of the stent. All failures oc-
curred in men. The two stents that failed were in a patient with
ureteral malignancy combined with ureteral damage from ra-
diotherapy, and percutaneous nephrostomy was needed in both
kidneys for adequate drainage. As other investigators have
shown, malignancy as an extrinsic cause generally produces
lower success rates than intrinsic causes.3 The same could likely
be applied to intrinsic malignancies of the urinary tract.
The median time to failure was 1.9 months. The median time
of follow-up in the successful cases was 9.9 months, more than
five times as long as the median time to failure. Therefore, we
are quite confident that the follow-up interval is long enough
to determine true failure.
While our study is one of the largest performed exclusively
regarding intrinsic causes of ureteral obstruction, there are dis-
advantages to the study. First, all of these procedures were per-
formed at a single institution. The type of patients treated at the
University of Michigan may be different from those at other in-
stitutions. Second, the 41 UUs analyzed had stent placement by
12 urologists at our institution. Of these, only three were fel-
lowship-trained endourologists at the time of the procedure.
One study has shown that placement technique may influence
symptoms with indwelling ureteral stents,15 and it is possible
that stent success or failure might also be related.
Finally, because we only considered patients in whom stent
placement was initially possible, our findings cannot be gener-
alized to predict the long-term success of stenting in all patients
who present with intrinsic ureteral obstruction.
CONCLUSION
Retrograde ureteral stenting for intrinsic ureteral compres-
sion was successful in 88% of patients when stent placement
was possible initially. Male sex, a moderately or severely hy-
dronephrotic kidney, and patients presenting with an increas-
ing creatinine level were more likely to have treatment failure
with a stent. Complications were rare. We advocate an attempt
at retrograde placement of ureteral stents in all patients with in-
trinsic ureteral obstruction.
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ABBREVIATIONS USED
CT  computed comography; UU  ureteral unit.
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